We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

MAPKAPK2 (MK2)

MK2 inhibitors act on MAPKAPK2, a protein kinase switched on by p38 MAP kinase in stress and inflammation. Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAPK2, MK2) was described in 1992 as a kinase activated by MAPK phosphorylation. Its substrates include heat shock protein 27 (HSP27) and proteins that control the stability of cytokine messenger RNAs. Mice lacking MK2 resist endotoxic shock and make far less tumor necrosis factor alpha (TNF-α) after lipopolysaccharide (LPS) challenge. PF-3644022 and MK2-IN-1 inhibit the kinase directly, and MMI-0100 is a cell-permeant peptide inhibitor. p38α-MK2-IN-1 targets the p38α-MK2 complex, and GLPG0259 is listed for the related kinase MAPKAPK5. Inhibitors of p38 itself, the upstream activator of MK2, are found under p38-MAPK.

1 Item

  • DB1113
    Cat. No.
    A24837
    CAS No.
    2769753-53-7

    DB1113

    DB1113 is a bifunctional compound designed for targeted protein degradation of various kinases. It effectively induces degradation of ABL1, ABL2, BLK, CDK4, CDK11B, EPHA3, MAPK7, RIPK1, and others, facilitating the investigation of kinase-related signaling pathways. DB1113 is suitable for research focusing on diseases or disorders associated with dysregulated kinase activity, providing a valuable tool for exploring therapeutic interventions in cancer and other conditions.

    In stock View Details
    5 mg
    $695.00
    10 mg
    $1,220.00
    All 2 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...